Market Data graphic

Sciences biologiques

Vous êtes ici

Le secteur des sciences biologiques comprend des sociétés dont les activités concernent les produits biopharmaceutiques, la fabrication et la distribution médicale et les produits biologiques.

Craftport Cannabis is a licensed producer of medical dried cannabis at its facility in Peachland, British Columbia. Through its 100-per-cent-owned subsidiary, Potanicals Green Growers Inc. ("Potanicals"), Craftport Cannabis received a production and cultivation license in October 2017 and a sales license from Health Canada in July 2019. The Health Canada sales license allows Craftport Cannabis to supply and sell finished cannabis products to provincial governments throughout Canada and through Canada's distribution and retail supply chain. Craftport Cannabis is providing recreational and medical dried cannabis, and will be providing capsules and other forms of cannabis products . As part of its expansion strategy Craftport Cannabis through its wholly-owned subsidiary and licensed producer Potanicals , has received its second cultivation license, effectively November 29, 2019, from Health Canada for the Company's joint venture greenhouse operations located in Pitt Meadows, BC.

Cresco Labs is one of the largest vertically-integrated multi-state cannabis operators in the United States. Cresco Labs is built to become the most important company in the cannabis industry by combining the most strategic geographic footprint with one of the leading distribution platforms in North America. Employing a consumer-packaged goods (“CPG”) approach to cannabis, Cresco Labs’ house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, Remedi and Mindy’s, a line of edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside*, Cresco Labs’ national dispensary brand, is a wellness-focused retailer designed to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs has launched the industry’s first national comprehensive Social Equity and Educational Development (SEED) initiative designed to ensure that all members of society have the skills, knowledge and opportunity to work in and own businesses in the cannabis industry.

(Note: In addition to the 329,438,439 Subordinate Voting Shares that are issued and outstanding, there are 110,466,357 Subordinate Voting Shares reserved for issuance pursuant to the redemption and conversion rights attached to: (i) the outstanding Proportionate Voting Shares of Cresco Labs Inc. that are not listed, and (ii) certain outstanding securities of Cresco Labs, LLC, which is a subsidiary of Cresco Labs, Inc. The total number of equity shares assuming all are converted into the listed class would be 439,904,796.)

Defence Therapeutics Inc. est une société de biotechnologie engagée dans la recherche et le développement, se concentrant sur l'amélioration de la fourniture de thérapies spécifiques aux tumeurs et aux maladies infectieuses. L'activité principale exercée est le développement d'une plate-forme de rehaussement de médicaments biologiques qui améliore l'efficacité et la sécurité d'une multitude de produits pharmaceutiques biologiques / biosimilaires utilisés dans le traitement du cancer et des maladies infectieuses.

Delota Corp. est un détaillant de vape et de cannabis établi qui organise et vend des produits liés à la vape et à la nicotine, d’autres produits de sevrage tabagique, des produits de cannabis et des accessoires lorsque la réglementation le permet. La Société exploite actuellement 28 magasins de vape spécialisés physiques en Ontario sous la bannière 180 Smoke Vape Store, une plateforme de commerce électronique de vape spécialisée (www.180smoke.ca) de premier plan à l’échelle du Canada, et cinq dispensaires autorisés sous le nom de Offside Cannabis en Ontario.

Digicann Ventures is a growth-oriented and diversified company focused on the international cannabis industry. The company is dedicated to the cultivation, distribution and marketing of high-quality cannabis and cannabis-infused products worldwide. Digicann Ventures’ primary asset in Canada is Boundary Bay Cannabis located in Delta, BC, which is one of the largest cannabis greenhouse facilities focused on the cost-optimized cultivation of high-potency cannabis. Abroad, the company’s wholly owned subsidiary, Farmako GmbH, is focused on becoming Europe’s leading distributor of medical cannabis. Farmako currently has active product distribution operations in Germany and is fully licensed in the United Kingdom.

Empatho Holdings Inc. est une entreprise de bien-être virtuel axée sur une solution intelligente alimentée par l'intelligence artificielle (IA) propriétaire PsychAI™, qui guide stratégiquement les utilisateurs pour atteindre leurs objectifs de bien-être. Empatho fournit une application mobile basée sur les données et utilisant une technologie de pointe pour impliquer les individus dans la gestion de leur propre santé, les aidant à devenir plus productifs et à découvrir des gains d'efficacité et des économies potentielles pour les employeurs.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders. 

FinCanna Capital Corp. (l'« émetteur ») n'a pas satisfait aux exigences d'inscription continue énoncées dans la politique 2 du CSE, annexe A, section 2A.6.

Conformément à l'article 3.5(2) de la Politique 3, l'Émetteur ne peut se fier à la protection confidentielle des prix, ni conclure un financement sans l'approbation préalable de la Bourse.

Conformément à la politique 3, section 3.5, l'extension .X est ajoutée aux titres cotés des émetteurs que la Bourse a jugés inactifs.

FSD Pharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma invented unbuzzd™ and spun it out its OTC version to a company, Celly Nutrition, led by industry veterans. FSD retains ownership of 25.71% (March 31, 2024) of Celly Nutrition Corp. at www.cellynutrition.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd ™ until payments to FSD Pharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, FSD Pharma retains a large tax loss carry forward of approximately CAD$130 million and could be utilized in the future to offset tax payable obligations against future profits. FSD Pharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical / medical uses. FSD Pharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.

Gaia Grow Corp. (la «Société») est un cultivateur agréé de chanvre industriel. Le modèle d’affaires de la société tire parti de l’agriculture contractuelle pour utiliser les terres agricoles existantes et des agriculteurs qualifiés pour cultiver du chanvre industriel, qu’elle vend ensuite aux transformateurs pour la transformer en fibres de chanvre et en huile et concentrés de cannabidiol. La société prévoit d'étendre ses activités pour inclure les magasins de vente au détail de cannabis en Colombie-Britannique.